Breaks Categories: News

TuesdayFeb 28, 2023 11:37 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Expands Advisory Board to Welcome Original ‘Shark’ and Visionary Kevin Harrington

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced that iconic entrepreneur Kevin Harrington has joined its advisory board. Harrington is world renowned as the inventor of the informercial, pioneer of the “As Seen on TV” brand, and one of the original “sharks” on the hit ABC show “Shark Tank.” He has launched more than 20 businesses as part of a career that has introduced 1,000+ products generating over $6 billion in global sales. “Kevin…

Continue Reading

TuesdayFeb 28, 2023 11:30 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Progress Updates on Two Clinical Development Programs

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is reporting on its two lead clinical development programs: CYB003, a proprietary deuterated psilocybin analog for the potential treatment of major depressive disorder (“MDD”), and CYB004, a proprietary deuterated N,N-dimethyltryptamine molecule being developed for the potential treatment of generalized anxiety disorder (“GAD”). According to the announcement, interim data from the CYB003 phase 1/2a study exhibited rapid and short-acting effects; strong psychedelic effects at low doses; and a positive safety and tolerability profile. The company anticipates having top-line efficacy data by late Q3 2023. In addition, initial…

Continue Reading

ThursdayFeb 23, 2023 10:05 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Plan to Streamline Efforts, Maximize Efficiency, Focus on Clinical Trials

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced a strategic plan designed to streamline efforts, maximize operating efficiency and focus on critical clinical trials, including near-term, mid-term and long-term milestones. A part of that plan was the release of an estimated 15% of Cybin’s workforce, including those in roles that were identified as not a clinical priority or not directly involved with any clinical trial initiatives. This move alone is expected to generate cost savings by reducing operating expenses. The announcement noted that with the anticipated cost savings from the overall streamlining…

Continue Reading

TuesdayFeb 21, 2023 2:42 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) CEO Featured in Recent “Authority” Magazine Interview

HeartBeam (NASDAQ: BEAT) CEO and founder Branislav Vajdic, PhD, is featured in a recent interview with David Leichner that was published in “Authority” magazine. The interview was one of a series of interviews with leaders of tech companies. The series, called “Technology Making an Important Positive Social Impact,” spotlights companies working on making monumental positive changes to society, health, and the environment. In the interview, Vajdic talked about his journey to HeartBeam, including the first half of his career, which was spent as a chip designer with Intel Corporation; Vajdic was involved in the design of the first Flash memory,…

Continue Reading

TuesdayFeb 21, 2023 11:19 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Interact with Leaders Pushing Boundaries of MS Research at Upcoming Forum

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced upcoming participation in the Americas Committee for Treatment and Research in Multiple Sclerosis (“ACTRIMS”) 2023 Forum taking place from Feb. 23-25 in San Diego, California, at the Marriott Marquis San Diego Marina. Founded in 1995, ACTRIMS is comprised exclusively of multiple sclerosis (“MS”) researchers and clinicians. “ACTRIMS provides us with an opportunity to interact with an esteemed community of leaders pushing the boundaries…

Continue Reading

TuesdayFeb 21, 2023 10:39 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q2 2023 Financial, Corporate Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, is reporting on its second quarter of fiscal year 2023, the period that ended Dec. 31, 2022. Highlights of the report include the company closing the calendar year with nearly $11.5 million in cash and the completion of enrollment in the company’s phase 2 clinical trial in epidermolysis bullosa (“EB”). The report also noted that the company has seen advancement in its research using rare cannabinoids in the treatment of glaucoma and neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s. “This…

Continue Reading

FridayFeb 17, 2023 12:31 pm

BioMedNewsBreaks – Psycheceutical Bioscience Inc. (BWVI) Inks Agreement for First-Ever Clinical Trials of a Proprietary Ketamine Topical Cream to Treat PTSD

Psycheceutical Bioscience (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, has entered into an exclusive agreement with iNGENū Pty Ltd., an Australian-based contract research organization. The agreement calls for iNGENū to conduct ​two human ​clinical trials of BWVI’s patented NeuroDirect(TM) ketamine topical ​in Australia. The first, a phase 1 trial, is designed to study 20 people and evaluate the safety, tolerability and pharmacokinetics of a single dose of NeuroDirect ketamine; the second, a phase 2 trial, is designed to study 115 participants diagnosed with post-traumatic stress disorder (“PTSD”) to evaluate the effectiveness…

Continue Reading

ThursdayFeb 16, 2023 3:47 pm

BioMedNewsBreaks – Aesther Healthcare Acquisition Corp. and Ocean Biomedical Inc. (NASDAQ: OCEA) Announce Approved Business Combination

Aesther, a special purpose acquisition company (“SPAC”) and Ocean Biomedical Inc. (NASDAQ: OCEA), a next-generation biopharma company, recently announced stockholder approval of all proposals related to the previously disclosed proposed business combination between Aesther and Ocean. According to the update, the approvals were secured at a special meeting of stockholders held on Feb. 3, 2023. The combined company, Ocean Biomedical, and its Class A common stock commenced trading on the Nasdaq Capital Market under the symbol OCEA. “I’m pleased that the majority of shareholders have, through their votes in favor of going public, reaffirmed their belief in our vision for…

Continue Reading

WednesdayFeb 15, 2023 12:17 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receives Confirmation of NASDAQ Compliance

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has regained compliance with NASDAQ continued listing requirements. The company announced that it has received confirmation from the exchange that it is in compliance with the minimum bid price requirement of $1 per share; the company currently meets all other applicable criteria for continued listing. In September 2022, FSD Pharma was notified that it was not in compliance with the Listing Rules of the Nasdaq Stock Market. On…

Continue Reading

WednesdayFeb 15, 2023 10:58 am

BioMedNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Releases Financial Report, Corporate Update for Q3

India Globalization Capital (NYSE American: IGC) (dba IGC Inc.) is reporting on its financial and corporate performance for the third fiscal quarter 2023. Highlights of the report include a focus on the company’s phase 2 clinical trial on IGC-AD1 for agitation in dementia from Alzheimer’s disease. The company reports that the number of sites participating in the trial has reached four: three sites in the United States and one site in Canada. In addition, based on patient enrollment and interest in the study, the company plans to more than double the number of trial sites, from the planned 4 or…

Continue Reading